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Abstract Asthma is a chronic inflammatory disease. Although many patients with asthma
develop type-2 dominated eosinophilic inflammation, a number of individuals develop
paucigranulocytic asthma, which occurs in the absence of eosinophilia or neutrophilia. The aetiology
of paucigranulocytic asthma is unknown. However, both respiratory syncytial virus (RSV) infection
and mutations in the receptor for advanced glycation endproducts (RAGE) are risk factors for
asthma development. Here, we show that RAGE deficiency impairs anti-viral immunity during an
early-life infection with pneumonia virus of mice (PVM; a murine analogue of RSV). The elevated
viral load was associated with the release of high mobility group box-1 (HMGB1) which triggered
airway smooth muscle remodelling in early-life. Re-infection with PVM in later-life induced many of
the cardinal features of asthma in the absence of eosinophilic or neutrophilic inflammation. Anti-
HMGB1 mitigated both early-life viral disease and asthma-like features, highlighting HMGB1 as a
possible novel therapeutic target.
DOI: 10.7554/eLife.21199.001
Introduction
Asthma is a chronic inflammatory disease of the airways that affects more than 300 million people
worldwide (Pawankar, 2014). The asthmatic airway is characterised by numerous structural changes
(collectively referred to as ‘airway remodelling’) including increased airway smooth muscle (ASM)
mass, sub-epithelial fibrosis and goblet cell hyperplasia/hypersecretion. Asthma is often considered
to be driven by type-2 eosinophilic inflammation (Lambrecht and Hammad, 2003). However,
approximately half of all patients with asthma do not exhibit eosinophilic inflammation, and accord-
ingly, other asthma phenotypes have been described that include neutrophilic, mixed granulocytic
and paucigranulocytic inflammatory phenotypes (Simpson et al., 2006;Hinks et al., 2016). Paucigra-
nulocytic asthma occurs in the absence of pronounced eosinophilia or neutrophilia and in the few
studies performed to date, is reported to affect between 32% and 52% of patients with asthma
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(Simpson et al., 2006; Schleich et al., 2013; Simpson et al., 2007; Porsbjerg et al., 2009;
Wang et al., 2011). At present, there is limited information available regarding the stability of this
phenotype and little is known about the pathogenic mechanisms or ‘endotype’ that underlies dis-
ease development.
The majority of asthma cases begin in early childhood. Interestingly, O’Reilly and colleagues
(O’Reilly et al., 2013) showed that wheezy preschool children displayed ASM remodelling prior to
their diagnosis of asthma as school aged children. Wheeze in children is often associated with a
lower respiratory tract infection, raising the possibility that paediatric viral infections contribute to
airway remodelling in early life and the subsequent development of asthma in later life. Consistent
with this notion, epidemiological studies have documented an association between severe respira-
tory syncytial virus (RSV) infection early in life and asthma development (James et al., 2013). Indeed,
persistent RSV-induced wheezing before 3 years of age is associated with chronic asthma persisting
into adulthood (Taussig et al., 1989; Wright et al., 1989). However, whether early life viral infec-
tions contribute to the development of paucigranulocytic asthma has yet to be investigated.
In addition to viral infections, specific immune signaling pathways have also been implicated in
the development of asthma. For example, we have previously shown that Tlr7-/- mice display the car-
dinal features of asthma following an earlier life and later life infection with pneumonia virus of mice
(PVM; a murine analogue of RSV) (Kaiko et al., 2013). This is consistent with the observation that,
compared to non-asthmatic individuals, TLR7 function is reduced in adolescents with asthma
(Roponen et al., 2010). There is also a growing body of evidence implicating high mobility group
box 1 (HMGB1) and the receptor for advanced glycation endproducts (RAGE) in disease develop-
ment (Sukkar et al., 2012). HMGB1 is an alarmin that acts as a non-histone nuclear protein in quies-
cent cells. Upon cell stimulation (such as by the presence of a pathogen) HMGB1 becomes
phosphorylated and is translocated from the nucleus to the cytoplasm. Upon release, extracellular
HMGB1 can bind to receptors such as RAGE, toll-like receptor (TLR) two and TLR4, and trigger a
pro-inflammatory response (Lotze and Tracey, 2005). Increased levels of HMGB1 have been
detected in the sputum of patients with asthma and high levels of HMGB1 have been associated
with reduced lung function (Hou et al., 2011).
The contribution of RAGE to asthma risk and symptoms is less well understood. This receptor is
expressed as membrane-bound (mRAGE) and soluble (sRAGE) forms; the latter is produced primarily
by shedding of mRAGE (Raucci et al., 2008) and is thought to function as a ‘decoy’ receptor, pre-
venting RAGE ligands from interacting with mRAGE, which would normally trigger inflammation
(Schmidt, 2015). Of note, a non-synonymous variant (rs2070600) in the AGER gene (which encodes
RAGE) is a strong determinant of serum sRAGE levels (Jang et al., 2007; Maruthur et al., 2015),
with the rs2070600:C allele (encoding a Gly at position 82) being associated with increased sRAGE.
This same allele is associated with decreased risk of allergic asthma (OR = 0.87, p=0.003 in
[Ferreira et al., 2014]). Taken together, the results from these genetic studies indicate that
decreased signalling through mRAGE (as a result of increased sRAGE production) might have a pro-
tective effect in allergic asthma. This prediction is complicated by the apparently conflicting observa-
tion that rs2070600:C (which results in increased sRAGE) is associated with decreased FEV1/FVC
ratio. However, it is important to note that this analysis was performed in the general population
(Repapi et al., 2010), and hence cannot be associated with asthma or allergic disease. Intriguingly,
RAGE deficiency or HMGB1 neutralisation ameliorates type-2 inflammation in preclinical models of
allergic asthma (Ullah et al., 2014). However, whether RAGE or HMGB1 contribute to viral bronchi-
olitis in early life, and the subsequent development of viral-induced asthma, remains to be
determined.
Here, using RAGE deficient mice and PVM infection we show that RAGE deficiency severely
impairs antiviral immunity. The resulting increase in viral load in the airway epithelium led to the
release of HMGB1, which via the activation of TLR4 was instrumental in driving ASM remodelling
during an early life viral infection, as well as the development of mucus hypersecretion and airway
hyperreactivity in later life. Critically, these features occurred independently of type-2 inflammation
and granulocytic inflammation, suggesting that blocking HMGB1 may be a promising therapeutic
approach to prevent the development of airway remodelling, which can occur in the absence of
eosinophilic or neutrophilic inflammation.
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Results
RAGE deficiency results in increased viral infection and reduced anti-
viral immunity during a PVM infection in early life
To understand the role of RAGE in an early life respiratory viral infection, seven-day old RAGE-defi-
cient (RAGE-) and wild-type (WT) mice were inoculated with PVM and viral infection was assessed by
qPCR at seven days post-infection (dpi). Day seven was selected as the time point of interest, as this
represents the peak of PVM replication in mice (Kaiko et al., 2013; Bonville et al., 2006). Infected
RAGE deficient mice had significantly higher levels of PVM RNA seven dpi compared to infected WT
mice (Figure 1A). However, in light of the fact that qPCR cannot differentiate between infectious
and non-infectious viral particles, and the fact that PVM titres are notoriously difficult to assess by
plaque assay (Dyer et al., 2007), we also measured active PVM infection by immunohistochemistry.
RAGE deficient mice displayed a significantly higher percentage of PVM infected airway epithelial
cells (AECs) in the respiratory tract compared to WT mice at seven dpi (Figure 1B & C). This
increased infection was associated with lower levels of IFNa, IFNl and IFNg in the BAL fluid and
lungs at seven dpi in PVM-infected RAGE deficient mice (Figure 1D & Figure 1E). Interestingly,
there was no significant difference in IFN production between mock- and PVM-infected RAGE defi-
cient mice, suggesting that RAGE deficient mice were unable to mount an IFN response following
infection with PVM (p>0.999). Consistent with this notion, PVM-infected RAGE deficient mice had
significantly lower expression of interferon regulatory factor (IRF7) (which regulates IFNa production)
relative to WT mice (Figure 1E).
pDCs are major producers of IFNa during infection (Tailor et al., 2006) and previous studies
have demonstrated that RAGE plays a key role in the mobilisation of these cells in mice
(Manfredi et al., 2008). We thus reasoned that the attenuated IFN production and associated
increased viral infection observed in RAGE deficient mice would be associated with defective pDC
recruitment. To determine whether lung pDCs expressed RAGE, we took advantage of the RAGE
deficient mouse in which the functional Ager gene is replaced by GFP. Using flow cytometry, we
demonstrated that pDCs derived from RAGE deficient mice were GFP+, indicating that under nor-
mal circumstances, wild-type lung pDCs express RAGE (Figure 1F). We next determined whether
the absence of RAGE would affect pDC recruitment to the lungs. At seven dpi, there were signifi-
cantly fewer pDCs in the lungs of PVM-infected RAGE deficient mice compared to PVM-infected WT
mice (Figure 1G), and similar to the IFN response, there was no significant difference in pDC recruit-
ment between mock- and PVM-infected RAGE deficient mice (Figure 1G) (p=0.6769). Together,
these data demonstrate that reduced IFN production in PVM-infected RAGE deficient mice is associ-
ated with a defect in pDC recruitment.
The absence of RAGE increases HMGB1 levels and ASM mass during
PVM infection in early life
Respiratory viral infections induce the production of various alarmins which may play an important
role in the development of asthma (Kaiko et al., 2013; You et al., 2015; Lloyd, 2010). Thus, we
measured the levels of the alarmins IL-33, IL-1a and HMGB1 in the lungs of neonatal WT and RAGE
deficient mice at seven dpi. Whilst the levels of IL-33 and IL-1a were elevated in infected WT mice,
there was no difference in expression between mock- and PVM-infected RAGE deficient mice
(Figure 2A) (p>0.999). In contrast, PVM-infected RAGE deficient mice had significantly higher levels
of HMGB1 in the BAL fluid compared to both mock-infected RAGE deficient mice and PVM-infected
WT mice (Figure 2A). PVM-infected RAGE deficient mice also had significantly higher levels of cyto-
plasmic HMGB1 in AECs compared to the other treatment groups (Figure 2B). These findings sug-
gest that loss of RAGE leads to a dramatic increase in HMGB1 release and that AECs are likely to be
an important source of this alarmin.
ASM remodelling is a hallmark feature of asthma that can commence in early life (O’Reilly et al.,
2013). Since HMGB1 has been implicated in smooth muscle proliferation (Porto et al., 2006), we
hypothesised that the elevated HMGB1 would induce ASM remodelling in early life. Indeed, there
was significantly more ASM mass in PVM-infected RAGE deficient mice compared to mock-infected
RAGE deficient mice and PVM-infected WT mice (Figure 2C). In contrast, PVM-infected WT mice
did not exhibit any increase in ASM growth compared to their mock-infected counterparts
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Figure 1. Increased virus replication and defective innate immunity in PVM-infected neonatal RAGE deficient mice.
(A) RAGE deficient (RAGE ) and WT (RAGE+) mice were infected with 10 PFU of PVM at seven days of age and the
viral load in the lungs (as determined by qPCR) was assessed 7 days post-infection (dpi). (B) Representative images
of PVM staining in the lungs of WT and RAGE deficient mice seven dpi. Arrow indicates positive staining. (C)
Figure 1 continued on next page
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(Figure 2C) (p>0.9999). Thus, in the absence of RAGE, an early life PVM infection is associated with
increased levels of HMGB1 and ASM mass.
Neutralising HMGB1 reduces PVM infection and ASM mass in RAGE
deficient mice during an early life PVM infection
In light of the association observed between extracellular HMGB1 levels and ASM mass, we next
investigated whether neutralisation of HMGB1 would prevent the induction of ASM remodelling.
Daily treatment of PVM-infected RAGE deficient mice with anti-HMGB1 antibody (50 mg) from 2 to 6
dpi significantly decreased the levels of extracellular HMGB1 in the BAL fluid (Figure 3A and B). The
number of AECs positive for cytoplasmic HMGB1 was also significantly decreased following anti-
HMGB1 treatment (Figure 3B). Importantly, ASM mass was significantly lower in RAGE deficient
mice that received anti-HMGB1 compared to isotype control antibody (Figure 3C). Anti-HMGB1
also significantly reduced the viral infection in the lungs of RAGE deficient mice (Figure 3D), and sig-
nificantly increased IFNa4 and IFNg expression in the lung compared to mice treated with the iso-
type control (Figure 3E). In contrast, anti-HMGB1 treatment did not affect viral load or ASM mass in
PVM-infected WT mice (Figure 4A–C) (p=0.1616 and p=0.5109). Together, these data demonstrate
that in the absence of RAGE, PVM infection increases ASM mass in an HMGB1 dependent manner.
RAGE/TLR4 deficient mice do not display increased ASM mass upon an
early life PVM infection
We next sought to identify the receptor through which HMGB1 signalled to trigger ASM remodel-
ling in RAGE deficient mice. As TLR4 is a known receptor for HMGB1 (Lotze and Tracey, 2005;
Ullah et al., 2014), we investigated viral load and ASM mass in mice deficient in both RAGE and
TLR4. There was no significant difference in viral load between PVM-infected RAGE/TLR4
deficient mice and PVM-infected RAGE deficient mice at seven dpi (Figure 5A) (p=0.1693). How-
ever, ASM growth was attenuated in RAGE/TLR4 deficient mice compared to RAGE deficient mice
(Figure 5B). TLR4 deficiency alone had no significant effect on either viral load or ASM mass when
compared to WT mice (Figure 5A and B) (p>0.9999).
Administration of exogenous IFN-a limits viral replication, ASM
remodelling and HMGB1 release in RAGE deficient mice during an earl
life PVM infection
The above data suggested that in the absence of RAGE, PVM-induced pDC recruitment is impaired
and there is decreased interferon production and increased viral infection. This is associated with
increased HMGB1 levels which then drives an increase in ASM mass. This model would thus suggest
that the addition of exogenous interferon would not only reduce virus replication in RAGE deficient
mice but that it would also reduce the levels of extracellular HMGB1 and ASM mass. In order to test
this hypothesis, neonatal RAGE deficient mice were treated with 5000 U of IFN-a or diluent alone at
three dpi. At seven dpi, the mice were euthanised and the viral load, HMGB1 levels and ASM mass
were assessed (Figure 6A). Exogenous IFN-a significantly decreased viral load in AECs compared to
mock-treated mice (Figure 6B). Moreover, both cytoplasmic and extracellular HMGB1 were
Figure 1 continued
Percentage of airway epithelial cells (AECS) positive for PVM by immunohistochemistry. (D) Interferon levels in the
bronchoalveolar lavage fluid of neonatal mice seven days post-PVM or mock infection (i.e. at 14-days of age). (E)
The expression of IFN-a4 and IRF7 in the lungs of RAGE deficient and WT mice seven dpi. The expression of IFN-
a4 and IRF7 was determined using the DDCt method where naı̈ve WT and RAGE deficient mice were used as the
calibrator samples. (F) Histogram demonstrating GFP expression by plasmacytoid dendritic cells (pDCs) derived
from naı̈ve adult RAGE deficient and WT mice. pDCs were defined as CD11c+CD11b-B220+SiglecH+CD45RA+
cells. (G) The number of pDCs presents in the lungs of neonatal mice seven days post-PVM or mock infection (i.e.
at 14-days of age). Statistical significance was determined by a Student’s t-test (A, C and E) or a two-way ANOVA
with Tukey’s multiple comparisons test (D and G). Statistical significance is denoted by asterisks (*p<0.05;**p<0.01;
***p<0.001; ns: not significant). Box and whisker plots show the minimum value, the median and the maximum
value. Data are representative of two independent experiments. n = 3–10.
DOI: 10.7554/eLife.21199.002
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Figure 2. PVM-infected neonatal RAGE deficient mice have higher levels of cytoplasmic and extracellular HMGB1.
(A) Levels of alarmins in the bronchoalveolar lavage fluid of neonatal mice. RAGE deficient (RAGE ) and WT
(RAGE+) mice were infected with 10 PFU of PVM or mock at 7 days of age and alarmin levels were assessed seven
dpi. (B) Representative images of mouse lung tissue sections stained for HMGB1 seven dpi (i.e. at 14-days of age).
Original magnification x400 and scale bars indicate 20 mm. HMGB1 staining is shown in red whilst the nucleus is
stained in blue. Arrows indicate cytoplasmic HMGB1, arrowheads indicate nuclear HMGB1. The percentage of
airway epithelial cells (AECs) with cytoplasmic HMGB1 was quantified as described in the materials and methods.
(C) Representative images of mouse lung tissue sections stained for smooth muscle actin seven dpi (i.e. at 14-days
of age). Original magnification x400 and scale bars indicate 20 mm. Smooth muscle staining is shown in red whilst
Figure 2 continued on next page
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significantly decreased in IFN-treated mice, and this was associated with a significant reduction in
ASM growth (Figure 6C and D).
PVM does not induce a pronounced type-2 response in neonatal RAGE
deficient mice
We have previously shown that TLR7 deficiency predisposes mice to severe PVM bronchiolitis and
an IFN-alow, IL-33high cytokine microenvironment (Kaiko et al., 2013). This response then leads to
the onset of type-2 inflammation early in life which, upon re-infection in later life, is re-activated to
promote the hallmark pathologies of asthma (Kaiko et al., 2013). Therefore, we next investigated
the inflammatory profile of RAGE deficient and WT mice following mock or PVM infection. Analysis
of the BAL cells by differential cell count showed that there was no significant difference in the num-
bers of eosinophils, neutrophils or lymphocytes between mock- and PVM-infected RAGE deficient
mice (Figure 7A) (p=0.1161; p=0.6107; p=0.0826 and p=0.8023). Consistent with the lack of an
eosinophilic response, IL-5 and IL-13 levels were not significantly elevated in the PVM-infected RAGE
deficient mice (Figure 7B) (p=0.7016 and p=0.9973) Levels of IL-17A were also not elevated in
RAGE deficient mice upon infection with PVM (Figure 7B). A similar trend was observed for eotaxin-
2, CXCL1 (KC), IL-12p40, IL-1b, IL-6, IL-23p19 and CCL3 (MIP-1a) levels in lung homogenates
(Figure 7C). Indeed, the only cytokine that was elevated in RAGE deficient mice upon infection with
PVM was TNF-a (Figure 7C). In order to confirm that the observed phenotype occurred in the
absence of a pronounced type-2 response, PVM-infected RAGE deficient mice were treated with sol-
uble IL-13Ra2 fusion protein (to neutralise IL-13) (Figure 8A). Blocking IL-13 failed to reduce viral
infection of AECs, ASM mass, or cytoplasmic HMGB1 levels in AECs (Figure 8B–D). (p=0.7422;
p=0.8369 and p=0.4266). Taken together, these data indicate the absence of a type-2 inflammatory
signature in neonatal RAGE deficient mice during PVM infection.
Re-infection of RAGE deficient mice with PVM induces the features of
asthma
In light of the ASM growth observed in neonatal RAGE deficient mice, we next questioned whether
a secondary PVM infection would promote features of airway wall remodelling characteristic of
asthma (Figure 9A). In contrast to the primary infection, viral antigen could not be detected in the
lungs of reinfected RAGE deficient mice at various time points post-infection, presumably as a con-
sequence of protective immunity (Figure 9B). Despite this, there was a significant increase in mucus-
secreting cells in re-infected RAGE deficient mice compared to re-infected WT mice (Figure 9C). Re-
infected RAGE deficient mice also displayed significantly higher levels of cytoplasmic HMGB1 in
AECs and extracellular HMGB1 compared to their WT counterparts (Figure 9D). Consistent with this
phenotype, re-infected RAGE deficient mice had more ASM mass compared to re-infected WT mice
(Figure 9E) and increased airway resistance compared to all other treatment groups (Figure 9F).
The number of ASM cells immunopositive for proliferating cell nuclear antigen (PCNA; a marker of
active cell replication) was also significantly increased in re-infected RAGE deficient mice at three
dpi compared to re-infected WT mice (Figure 10A and B). Taken together, these data indicated
that in the absence of RAGE, re-infection with PVM induces some of the pathophysiological features
of asthma.
RAGE deficiency and secondary PVM infection predispose towards a
paucigranulocytic asthma-like phenotype
In light of the goblet cell hyperplasia, airway hyperreactivity and increased ASM mass, we next ques-
tioned whether re-infected RAGE deficient mice had developed a type-2 response as we have
Figure 2 continued
the nucleus is stained in blue. Arrow indicates positive staining. The airway smooth muscle area (ASM) was
calculated relative to the basement membrane (BM) length of small airways. Statistical significance was
determined by a two-way ANOVA with Tukey’s multiple comparisons test. Statistical significance is denoted by
asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not significant). Box and whisker plots show the minimum value, the
median and the maximum value. Data are representative of two independent experiments. n = 3–6.
DOI: 10.7554/eLife.21199.003
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Figure 3. Blocking HMGB1 reduces ASM mass and virus replication in neonatal, PVM-infected RAGE deficient
mice. (A) Schematic representation of the experimental protocol. Neonatal RAGE deficient mice were infected
with 10 PFU of PVM at 7 days of age and treated with 50 mg of anti-HMGB1 or an IgG isotype control once per
day from two to six days post-infection. (B) Levels of extracellular HMGB1 in the bronchoalveolar lavage fluid of
Figure 3 continued on next page
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previously observed in TLR7 deficient mice (Kaiko et al., 2013). Similar to the primary PVM infec-
tion, the inflammatory response in the BAL (defined by the number eosinophils, neutrophils, mono-
nuclear cells and lymphocytes) of re-infected RAGE deficient mice was comparable to WT mice and
markedly lower than that of re-infected TLR7 deficient mice(Figure 11A). Similarly, IL-5, IL-13, peri-
ostin (a marker of type-2 inflammation) (Jia et al., 2012) and eotaxin-2 were not increased in RAGE
deficient mice upon re-infection with PVM (Figure 11B & C) (p=0.8815, p>0.9999 and p>0.9999).
Whilst an increase in CXCL1(KC) was observed in the lungs upon re-infection in RAGE deficient
mice, this response was significantly lower than that of WT mice (Figure 11C). Therefore, the fea-
tures of asthma observed in re-infected RAGE deficient mice resembled what is described in humans
as paucigranulocytic asthma.
Neutralising HMGB1 in re-infected RAGE deficient mice prevents the
cardinal features of asthma
HMGB1 played an important role in driving ASM remodelling during the primary PVM infection.
Therefore, we next assessed whether neutralising HMGB1 would protect RAGE deficient mice from
developing the features of asthma following re-infection with PVM. RAGE deficient mice were
Figure 3 continued
treated mice seven days post-PVM infection. The percentage of airway epithelial cells (AECs) with cytoplasmic
HMGB1 in treated mice is also displayed seven days post-PVM infection. (C) Lung sections were obtained from
treated mice seven days post-PVM infection (i.e. at 14-days of age). These were then stained for smooth muscle
actin by immunohistochemistry and the airway smooth muscle area (ASM) was calculated relative to the basement
membrane (BM) length of small airways. (D) Percentage of airway epithelial cells (AECS) positive for PVM in treated
mice seven days post-PVM infection (i.e. at 14-days of age). (E) Interferon levels in the bronchoalveolar lavage fluid
of treated mice seven days post-PVM infection (i.e. at 14-days of age). Statistical significance was determined by a
Student’s t-test. Statistical significance is denoted by asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not significant).
Box and whisker plots show the minimum value, the median and the maximum value. Data are derived from a























































Figure 4. Blocking HMGB1 does not reduce ASM mass and virus replication in neonatal, PVM-infected WT mice.
(A) Schematic representation of the experimental protocol. Neonatal WT mice were infected with 10 PFU of PVM
at seven days of age and treated with 50 mg of anti-HMGB1 or an IgG isotype control once per day from two to six
days post-infection. (B) Percentage of airway epithelial cells (AECS) positive for PVM in treated mice seven days
post-PVM infection (i.e. at 14-days of age). (C) Lung sections were obtained from treated mice seven days post-
PVM infection (i.e. at 14-days of age). These were then stained from smooth muscle actin by
immunohistochemistry and the airway smooth muscle area (ASM) was calculated relative to the basement
membrane (BM) length of small airways. Statistical significance was determined by a Student’s t-test. Statistical
significance is denoted by asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not significant). Box and whisker plots show
the minimum value, the median and the maximum value. Data are derived from a single experiment. n = 6.
DOI: 10.7554/eLife.21199.005
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Figure 5. ASM mass is reduced in PVM-infected RAGE/TLR4 deficient mice. (A) Percentage of airway epithelial
cells (AECS) positive for PVM by immunohistochemistry. RAGE deficient, WT (RAGE+), TLR4 deficient and RAGE/
TLR4 deficient mice were infected with 10 PFU of PVM at 7 days of age and the viral infection was assessed seven
days post-infection. (B) Lung sections were obtained from neonatal RAGE deficient, WT, TLR4 deficient and
RAGE/TLR4 deficient mice seven days post-PVM infection (i.e. at 14-days of age). These were then stained from
smooth muscle actin by immunohistochemistry and the airway smooth muscle area (ASM) was calculated relative
to the basement membrane (BM) length of small airways. Statistical significance was determined by a two-way
ANOVA with Tukey’s multiple comparisons test. Statistical significance is denoted by asterisks (*p<0.05;**p<0.01;
***p<0.001; ns: not significant). Box and whisker plots show the minimum value, the median and the maximum
value. Data are representative of two independent experiments. n = 5–8.
DOI: 10.7554/eLife.21199.006
A) B) C) D)





















































































3 dpi 7 dpi
Figure 6. Interferon supplementation reduces virus replication, levels of extracellular HMGB1 and ASM mass and in neonatal, PVM-infected RAGE
deficient mice. (A) Schematic representation of the experimental protocol. Neonatal RAGE deficient mice were infected with 10 PFU of PVM at seven
days of age. Three days post-infection 5000 U of IFN-a or diluent only was administered intranasally to the mice. (B) Percentage of airway epithelial
cells (AECS) positive for PVM in treated mice seven days post-PVM infection (i.e. at 14-days of age). (C) The percentage of airway epithelial cells (AECs)
with cytoplasmic HMGB1 seven days post-PVM infection in treated mice. Levels of extracellular HMGB1 in the bronchoalveolar lavage fluid of treated
mice seven days post-PVM infection is also displayed. (D) Lung sections were obtained from treated mice seven days post-PVM infection (i.e. at 14-days
of age). These were then stained for smooth muscle actin by immunohistochemistry and the airway smooth muscle area (ASM) was calculated relative
to the basement membrane (BM) length of small airways. Statistical significance was determined by a Student’s t-test. Statistical significance is denoted
by asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not significant). Box and whisker plots show the minimum value, the median and the maximum value.
Data are representative of two independent experiments. n = 5–7.
DOI: 10.7554/eLife.21199.007
Arikkatt et al. eLife 2017;6:e21199. DOI: 10.7554/eLife.21199 10 of 25




































































































































































































































































































































Figure 7. Neonatal RAGE deficient mice do not display a pronounced TH2 response to an early life infection with PVM. RAGE deficient and WT
(RAGE+) mice were infected with 10 PFU of PVM or mock at seven days of age and the inflammatory profile was assessed seven days post-infection (A)
Inflammatory cells in the bronchoalveolar lavage fluid were enumerated by differential counting following Geimsa staining. (B) Cytokine levels in the
bronchoalveolar lavage fluid of neonatal mice seven days post-PVM or mock infection (i.e. at 14-days of age). (C) Cytokine levels in the lungs of
neonatal mice seven days post-PVM or mock infection (i.e. at 14-days of age). Statistical significance was determined by a one-way ANOVA with Tukey’s
multiple comparisons test (A) or a two-way ANOVA (B and C). Statistical significance is denoted by asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not
Figure 7 continued on next page
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treated daily for four days from the time of re-infection with anti-HMGB1 or an isotype-matched con-
trol (Figure 12A). Anti-HMGB1 significantly decreased the levels of cytoplasmic HMGB1 in AECs at
seven dpi compared to treatment with the isotype control (Figure 12B). Importantly, anti-HMGB1
treated RAGE deficient mice also displayed significantly reduced goblet cell hyperplasia, ASM mass
and AHR compared to control treated RAGE deficient mice (Figure 12C–E).
RAGE/TLR4 deficient mice are protected from developing the cardinal
features of asthma upon re-infection with PVM
Given that in the primary infection the increase in ASM mass was TLR4 dependent, we next sought
to investigate if TLR4 in later life contributed to the development goblet cell hyperplasia, ASM mass
and AHR. Thus, WT, RAGE deficient, TLR4 deficient and RAGE/TLR4 deficient mice were inoculated
with PVM at seven days of age and later re-infected with mock or PVM 42fi days after the primary
infection. Re-infected RAGE/TLR4 deficient mice had significantly fewer mucus secreting cells in the
lung and displayed reduced ASM mass seven dpi compared to re-infected RAGE deficient mice
(Figure 13A and B). Although there was no significant difference in AHR between the two mouse
strains (p>0.9999), there was a trend towards decreased AHR in re-infected RAGE/TLR4 deficient
mice (Figure 13C). To determine if the features of airway remodelling persisted, mice were re-
assessed 21 days after re-infection. Goblet cell hyperplasia, ASM mass and AHR were elevated in
RAGE deficient mice compared to WT mice (Figure 13D–F). Once again, these features were absent
in RAGE/TLR4 deficient mice (Figure 13D–F), suggesting that TLR4 plays an important role in the
development of the observed asthma phenotype.
Discussion
Multiple genetic and environmental factors are implicated in the pathogenesis of asthma , and these
gene-environment interactions most likely underpin the different endotypes that give rise to
Figure 7 continued
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Figure 8. Blocking IL-13 does not reduce ASM mass and virus replication in neonatal, PVM-infected RAGE deficient mice. (A) Schematic representation
of the experimental protocol. Neonatal RAGE deficient mice were infected with 10 PFU of PVM at seven days of age and treated i.p. with 100 mg of sIL-
13Ra2-Fc or an IgG isotype control once per day from two to six days post-infection. (B) Percentage of airway epithelial cells (AECS) positive for PVM in
treated mice seven days post-PVM infection (i.e. at 14-days of age). (C) The percentage of airway epithelial cells (AECs) with cytoplasmic HMGB1 in
treated mice seven days post-PVM infection. (D) Lung sections were obtained from treated mice seven days post-PVM infection (i.e. at 14-days of age).
These were then stained for smooth muscle actin by immunohistochemistry and the airway smooth muscle area (ASM) was calculated relative to the
basement membrane (BM) length of small airways.). Statistical significance was determined by a Student’s t-test. Statistical significance is denoted by
asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not significant). Box and whisker plots show the minimum value, the median and the maximum value. Data
are derived from a single experiment. n = 5–6.
DOI: 10.7554/eLife.21199.009
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Figure 9. Reinfection with PVM induces the cardinal features of asthma in adult RAGE deficient mice. (A)
Schematic representation of the experimental protocol. Neonatal WT (RAGE+) and RAGE deficient mice were
inoculated with PVM (10 PFU) or mock at seven days of age and later re-infected with PVM (100 PFU) or mock 42
days after the primary infection. (B) Representative images of PVM staining in the lungs of RAGE deficient mice at
various timepoints post-infection. (C) Percentage of airway epithelial cells (AECs) producing mucus was quantified
by immunohistochemistry at seven days post-reinfection (i.e. at 56-days of age). (D) The percentage of airway
epithelial cells (AECs) with cytoplasmic HMGB1 three days post re-infection (i.e. at 52-days of age). Levels of
extracellular HMGB1 in the bronchoalveolar lavage fluid of mice three days post re-infection (i.e. at 52-days of age)
are also displayed. (E) Lung sections from WT and RAGE deficient mice seven days post re-infection (i.e. at 56-
days of age) were stained for smooth muscle actin by immunohistochemistry and the airway smooth muscle area
(ASM) was calculated relative to the basement membrane (BM) length of small airways. (F) Airway hyperreactivity
to increasing doses of aerosolised methacholine (MCh) at seven days post-reinfection (i.e. at 56-days of age).
Statistical significance was determined by a two-way ANOVA with Tukey’s multiple comparisons test (B, D and E)
or a Student’s t-test (C). Statistical significance is denoted by asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not
Figure 9 continued on next page
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different phenotypes of asthma. In the present study, we demonstrated impaired pDC recruitment
and decreased production of IFN-a, -g, -l in RAGE deficient mice during an early life PVM infection,
resulting in a higher viral load in the airway epithelium. The increased viral replication in neonatal
RAGE deficient mice observed in this study was associated with the extracellular release of HMGB1,
most likely as a consequence of virus-induced AEC stress. Increased levels of HMGB1 then drove an
increase in ASM mass. This increase in ASM mass was dependent upon TLR4. Re-inoculation of
RAGE deficient mice with PVM later in life, whilst resulting in a non-productive infection, exacer-
bated ASM growth and induced other characteristic features of asthma such as mucus hyper-secre-
tion and airway hyperreactivity (Figure 14). Importantly, this asthma-like phenotype occurred in the
absence of a pronounced eosinophilic or neutrophilic response. Thus, this model represents, to the
best of our knowledge, the first mouse model that recapitulates the cardinal features of paucigranu-
locytic asthma.
In the present study anti-HMGB1 treatment in RAGE deficient mice reduced the levels of cyto-
plasmic HMGB1, which was associated with reduced airway remodelling (both in early and later life).
The ability of anti-HMGB1 treatment to reduce cytoplasmic HMGB1 staining most likely reflects the
ability of this antibody to inhibit extracellular HMGB1. Upon its release, HMGB1 can act back on cells
to induce de novo HMGB1 synthesis and its release, to amplify the inflammatory response
(Porto et al., 2006). Therefore, blocking extracellular HMGB1 can indirectly lower intracellular levels
of HMGB1. Previous studies have also demonstrated that extracellular HMGB1 can be internalised
(Xu et al., 2014). Thus, we cannot exclude the possibility that blocking extracellular HMGB1 reduced
intracellular HMGB1 by decreasing HMGB1 uptake (Xu et al., 2014). However, it is important to
note that HMGB1 internalisation is a RAGE-dependent process (Xu et al., 2014) and hence less
likely to be relevant in RAGE deficient mice.
At present, it remains to be determined how HMGB1 induces ASM growth. HMGB1 can induce
smooth muscle proliferation in vitro (Porto et al., 2006), suggesting that HMGB1 is capable of
Figure 9 continued
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Figure 10. Reinfection with PVM induces airway smooth muscle proliferation in RAGE deficient mice. Neonatal
mice were infected with PVM (10 PFU) at seven days of age and later re-infected with PVM (100 PFU) 42 days after
the primary infection. (A) Representative immunofluorescent image (60X magnification) showing ASM cell
proliferation in RAGE deficient mice three days post re-infection (i.e. at 52 days of age). ASM (green), PCNA (red)
and DAPI (blue). Arrow indicates positive PCNA staining (H) The percentage of airway smooth muscle (ASM) cells
positive for PCNA overtime. Statistical significance was determined by a two-way ANOVA with Tukey’s multiple
comparisons test. Statistical significance is denoted by asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not significant).
Box and whisker plots show the minimum value, the median and the maximum value. Data are representative of
two independent experiments. n = 5–7.
DOI: 10.7554/eLife.21199.011
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mediating ASM growth in the absence of any other intermediary signalling molecule. Interestingly,
blocking HMGB1 during the primary PVM infection also served to increase IFN–a and IFN-l produc-
tion and reduced viral load in RAGE deficient mice. We did not explore the mechanism by which
anti-HMGB1 augments IFN production in our model. However, HMGB1 can inhibit IFN-a production
by pDCs in response to CpG containing DNA (Lotze and Tracey, 2005), highlighting an important
role for HMGB1 in regulating type I interferon responses.
The data presented herein raise the intriguing possibility that blocking HMGB1 may be a novel


















































































































































































































Figure 11. RAGE deficient mice do not display a pronounced TH2 response upon re-infection with PVM. Neonatal WT (RAGE
+), TLR7 deficient and
RAGE deficient mice were infected with PVM (10 PFU) or mock at seven days of age and later re-infected with PVM (100 PFU) or mock 42 days after the
primary infection. (A) Inflammatory cells in the bronchoalveolar lavage fluid were enumerated by differential counting following Geimsa staining seven
days post-reinfection (i.e. at 56-days of age). (B) Cytokine levels in the bronchoalveolar lavage fluid of neonatal mice seven days post-re infection (i.e. at
56-days of age). (C) Cytokine levels in the lungs of neonatal mice seven days post- reinfection (i.e. at 56-days of age). Periostin levels were determined
by immunohistochemistry and quantified as a percentage of the epithelial basement membrane length. Statistical significance was determined by a
Student’s t-test (A) and a two-way ANOVA with Tukey’s multiple comparisons test (B and D). Statistical significance is denoted by asterisks (*p<0.05;
**p<0.01; ***p<0.001; ns: not significant). Box and whisker plots show the minimum value, the median and the maximum value. Data are representative
of two independent experiments. n = 4–9.
DOI: 10.7554/eLife.21199.012
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Figure 12. Anti-HMGB1 treatment following re-infection with PVM protects against asthma development in RAGE
deficient mice. (A) Schematic representation of the experimental protocol. RAGE deficient mice were infected with
10 PFU of PVM at seven days of age and later re-infected with 100 PFU of PVM 42 days post-primary infection.
RAGE deficient mice were treated once per day from day zero to day four post-reinfection with 50 mg of an anti-
HMGB1 antibody or an IgG isotype control. (B) The percentage of airway epithelial cells (AECs) with cytoplasmic
HMGB1 seven days post-PVM re-infection in treated mice (i.e. at 56-days of age). (C) Percentage of airway
epithelial cells (AECs) producing mucus in the lungs of treated mice was quantified by immunohistochemistry at
seven days post-reinfection (i.e. at 56-days of age). (D) Lung sections were obtained from treated mice seven days
post re-infection (i.e. at 56-days of age). These were then stained for smooth muscle actin by
immunohistochemistry and the airway smooth muscle area (ASM) was calculated relative to the basement
membrane (BM) length of small airways. (E) Airway hyperreactivity to increasing doses of aerosolised methacholine
(MCh) in treated mice at seven days post-reinfection (i.e. at 56-days of age). Statistical significance was determined
by a Student’s t-test (A–C) and a two-way ANOVA with Tukey’s multiple comparisons test (D). Statistical
significance is denoted by asterisks (*p<0.05;**p<0.01; ***p<0.001; ns: not significant). Box and whisker plots show
the minimum value, the median and the maximum value. Data are derived from a single experiment. n = 5.
DOI: 10.7554/eLife.21199.013
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Although this hypothesis requires further investigation, blocking HMGB1 could be an approach that
is readily translated to the clinic given that anti-HMGB1 treatments have already been approved for
clinical trials to block systemic inflammation (Ulloa and Messmer, 2006). Interestingly, several of the
viruses and bacteria that have been implicated in the pathogenesis of asthma are also known to
induce HMGB1 (Moisy et al., 2012; Hou et al., 2014; Wang et al., 2004, 1999). Indeed, our prelim-
inary data suggest that later life exposure to either influenza A virus or lipopolysaccharide (known
HMGB1 stimuli) (Nosaka et al., 2015; Gardella et al., 2002) are able to induce at least some fea-
tures of airway remodelling in RAGE deficient mice that were infected with PVM in early life (data
not shown). These data thus also raise the possibility that the mechanisms of disease shown here
may not be limited to PVM-induced asthma. Similarly, we previously identified that HMGB1 was






























































































































































































































Figure 13. RAGE/TLR4 deficient mice are protected from asthma development following re-infection with PVM. Neonatal mice were infected with PVM
(10 PFU) or mock at seven days of age and later re-infected with PVM (100 PFU) or mock 42 days after the primary infection. (A) Percentage of airway
epithelial cells (AECs) producing mucus in the lungs of treated mice was quantified by immunohistochemistry at seven days post-reinfection (i.e. at 56-
days of age) and (D) 21 days post-reinfection (i.e. at 70-days of age). (B) Lung sections were obtained from WT and RAGE deficient mice seven days
post re-infection (i.e. at 56-days of age) and (E) 21 days post-reinfection (i.e. at 70-days of age). These were then stained for smooth muscle actin by
immunohistochemistry and the airway smooth muscle area (ASM) was calculated relative to the basement membrane (BM) length of small airways. (C)
Airway hyperreactivity to increasing doses of aerosolised methacholine (MCh) in treated mice at seven days post-reinfection (i.e. at 56-days of age).
Statistical significance is denoted by asterisks (one symbol p<0.05;two symbols p<0.01; three symbols p<0.001; ns: not significant). Statistical
significance is shown relative to WT mice (*) and TLR4 deficient (^) mice. (F) Airway hyperreactivity to increasing doses of aerosolised methacholine
(MCh) in treated mice at 21 days post-reinfection (i.e. at 70-days of age). Statistical significance was determined by a two-way ANOVA with Tukey’s
multiple comparisons test. Statistical significance is denoted by asterisks (one symbol p<0.05;two symbols p<0.01; three symbols p<0.001; ns: not
significant). Statistical significance is shown relative to WT mice (*), TLR4 deficient (^) and RAGE/TLR4 deficient mice (#). Box and whisker plots show the
minimum value, the median and the maximum value. Data are representative of two independent experiments. n = 3–6.
DOI: 10.7554/eLife.21199.014
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(Ullah et al., 2014). Collectively, these findings and others highlight a central role for HMGB1 in the
pathogenesis of multiple subtypes of asthma.
The redox state of HMGB1 controls which host receptors it will interact with. Specifically, when
the cysteine in location C106 is in the reduced thiol form and C23 and C45 are involved in a disul-
phide bridge (HMGB1C23–C45C106h, disulphide HMGB1), HMGB1 functions as a TLR4 ligand
(Yang et al., 2012, 2010). In light of the fact that TLR4 was essential for ASM growth and the cardi-
nal features of asthma in this model, it is tempting to speculate that disulphide HMGB1/TLR4 inter-
actions are sufficient to induce early life airway remodelling and the development of asthma later in
life. This is consistent with the fact that the protective anti-HMGB1 antibody used in the present
study blocks all-thiol and disulphide HMGB1 (Yang et al., 2010, 2012; Zhu et al., 2015). Thus, the
specific role of disulphide HMGB1 in the development of asthma represents an area of ongoing
investigation.
Whilst the absence of both TLR7 and RAGE mediate asthma via similar mechanisms (i.e. a defec-
tive interferon response and an increase in ASM mass), this study showed that PVM-infected RAGE
deficient mice displayed a markedly different inflammatory profile to that which we previously
described in PVM-infected TLR7 deficient mice (Kaiko et al., 2013). Compared to TLR7 deficient
mice, re-infected RAGE deficient mice did not develop type-2 eosinophilic inflammation nor did
they generate a neutrophilic response. In TLR7 deficient mice, the type-2 inflammation was under-
pinned by an IFN-alow/IL-33high cytokine microenvironment (Kaiko et al., 2013), whereas the
absence of RAGE attenuated the production of both IFN–a and IL-33. Others have demonstrated
that RAGE deficient mice produce lower levels of both type-1 and type-2 cytokines in an ovalbumin
model of allergic asthma (Akirav et al., 2014). Similarly, we have previously shown that type-2 eosin-
ophilic inflammation, induced in response to either house dust mite or cockroach sensitisation/chal-
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Figure 14. A schematic representation of the proposed model of disease. During a primary PVM infection, reduced interferon production results in
increased virus replication. This is then associated with the release of HMGB1 (assumedly due to virus-induced stress/damage). In a TLR4-dependent
fashion, HMGB1 drives the growth of airway smooth muscle (ASM). Upon reinfection with PVM later in life, there is no active virus replication
(presumably due to a protective immune response). However, exposure to PVM triggers the production of HMGB1 which then drives ASM growth and
mucus production in a TLR4 dependent manner.
DOI: 10.7554/eLife.21199.015
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the activation of RAGE contributes to type-2 inflammation remains poorly defined. However, it is
noteworthy that RAGE is necessary for the lung infiltration of type-2 innate lymphoid cells
(Oczypok et al., 2015), a cell type that is increasingly implicated in the priming and amplification of
type two immunity (Oliphant et al., 2014). Similarly, the absence of a pronounced neutrophilic
response in re-infected RAGE deficient mice is consistent with the role of RAGE in neutrophil recruit-
ment (Orlova et al., 2007). Thus, although HMGB1-mediated activation of RAGE promotes type-2
inflammation (which is known to induce the hallmark pathologies of asthma), in the absence of
RAGE HMGB1 can directly induce features of airway remodelling and thus contribute to airway
hyperreactivity independently of type-2 inflammation.
Paucigranulocytic asthma is a poorly understood subtype of asthma. The mechanism of airway
hyperreactivity and remodelling in these patients remains unclear, and indeed HMGB1 levels,
although known to be elevated in eosinophilic asthma (Watanabe et al., 2011) have never been
thoroughly investigated in in paucigranulocytic asthma. Moreover, whether specific genetic muta-
tions lead to a propensity to develop pauciogranulocytic asthma (instead of, for example, eosino-
philic asthma) has yet to be studied. However, the data presented here suggest that defective
RAGE signaling contributes to the development and progression of airway remodeling in the
absence of Th2/Th17-mediated granulocytic inflammation Given that we identified HMGB1 as a cen-
tral mediator in the pathogenesis of airway remodelling, our findings suggest that anti-HMGB1 ther-




C57BL/6 wild-type (WT) mice were purchased from the University of Queensland (Brisbane, Aus-
tralia). RAGE-deficient mice were kindly provided by Prof. Ann-Marie Schmidt (New York University
Langone Medical Centre, USA). TLR4 deficient mice were provided by Dr. Matthew Sweet (Institute
for Molecular Bioscience, University of Queensland, Australia). TLR4 deficient mice were cross-bred
with RAGE deficient mice to generate RAGE/TLR4 deficient mice. TLR7 deficient mice were pro-
vided by Prof. John Hayball (University of South Australia, Adelaide). All mice were on a C57BL/6
background, and rederived into a SPF facility prior to experimentation. Mice were housed in individ-
ually ventilated cages, on a 12 hr controlled day/night cycle with food and water available ad libitum.
Dams were monitored daily from day 14 of gestation for litter birth. At 3 days of age, litter size of 6–
8 pups per experimental group was standardised. The study was approved by the Animals Ethics
Committee, University of Queensland (Ethics number 209/13).
Virus strain
Stocks of PVM strain J3666 were prepared from mouse lung homogenates as described previously
(Garvey et al., 2005).
Infection and treatment of mice
Viral inoculums were prepared in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, Carlsbad,
U.S.A.) containing 10% heat-inactivated Foetal Bovine Serum (FBS) (10% v/v) (Sigma-Aldrich, St
Louis, U.S.A.). Diluent alone was used for mock infections. The response to PVM in neonatal mice
was assessed by infecting seven-day old mice intranasally with 10 plaque forming units (PFU) of PVM
or mock in a volume of 10 mLs. Where relevant, 42-days after the primary infection, mice were re-
infected intranasally with 100 PFU of PVM or mock in a total volume of 50 mL. All intranasal infections
were administered under isofluorane-induced anaesthesia. Where indicated, mice were treated intra-
nasally with 5000U of mouse IFN-a (HyCult Biotechnology, Uden, the Netherlands), PBS, 50 mg of
anti-HMGB1 antibody (kindly provided by Prof. Kevin J Tracey, Feinstein Institute of Medical
Research, NY, USA) or an IgG isotype (eBioscience, CA, USA). The selected dose of IFN-a was based
upon the findings of previous studies (Nakajima et al., 1994).
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Flow cytometry
Lungs were mechanically dissociated using a syringe plunger and 70 mm nylon cell strainer and sin-
gle-cell suspensions were prepared. Alternatively, bone marrow-derived pDCs grown in culture were
washed and resuspended in FACS buffer (PBS/2%FBS). Cells were incubated with 10 ng/ml of
FcgRIII/II (Fc block; BD Biosciences) then stained for CD45RA (PE; clone 14.8, BD Biosciences),
CD11c (V450; clone HL3, BD Biosciences) CD11b (V500, clone M1/70, BD Biosciences), Siglec H
(APC, clone eBio440c, eBioscience) and B220 (PerCP-Cy5.5, clone RA3-6B2, eBioscience). Cells were
fixed in formalin (0.5% v/v) and acquired using an LSRII flow cytometer (BD Bioscience).
Bronchoalveolar lavage (BAL) collection and analysis of inflammatory
cells
Lung lobes were lavaged with 400 ml (for neonatal mice) or 600 ml (for adult mice) of ice-cold PBS.
Cells were pelleted by centrifugation and treated with red blood cell (RBC) lysis buffer. A StatSpin
cytofuge was used at 600 rpm for 7 min to achieve a monolayer of leukocytes on triethoxysilane
(Sigma-Aldrich) treated slides. 24 hr later the cells were fixed in 100 % v/v methanol for 15 min and
stored until histological staining was ready to be performed. The slides were stained with May-Grun-
wald Giemsa solution (Sigma-Aldrich). Differential counts were performed using standard morpho-
logical criteria to classify cells as macrophages, lymphocytes, neutrophils and eosinophils.
Immunohistochemistry
The superior right lung lobe was fixed in 10% neutral buffered formalin, embedded in paraffin, sec-
tioned at 5 mm and subsequently used for immunohistochemistry. Antigen retrieval was performed
by boiling the slides in 10 mM citrate buffer (pH 6) in a pressure cooker for 10 min. Sections were
permeabilised using 0.5% Triton or 0.6% Tween-20 and blocked with 10% normal goat serum
(Sigma-Aldrich). Slides were incubated with the relevant primary antibody overnight at 4˚C (see
Table 1). The relevant secondary antibody (Goat anti-rabbit-AP [Sigma-Aldrich], Goat anti-mouse AP
[Sigma-Aldrich] or Streptavidin-AP [GE Healthcare Biosciences, NJ, U.S.A.]) was added to sections
for 1 hr at room temperature and colour was developed using the Fast Red substrate (Sigma-
Aldrich). Sections were counterstained with haematoxylin and mounted with Glycergel (Dako, CA, U.
S.A.). Viral load was assessed as the percentage of airway epithelial cells positive for PVM on the api-
cal surface and in the cytoplasm. Cytoplasmic HMGB1 was quantified as percentage of airway epi-
thelial cells positive for HMGB1 in the cytoplasm. ASM was quantified essentially as described
previously (Lynch et al., 2016) and was calculated as the Harea (mm2)/ basement membrane length
(mm) of small airways (airway circumference <500 mm quantified for neonates and <800 mm for adult
mice). To identify mucus producing cells, sections were stained with Periodic Acid-Schiff (PAS) and
then counterstained with Harris’ hematoxylin (Dako) and mounted in DEPEX. Mucus production was
scored based on the percentage of mucus secreting AECs relative to the total number of AECs. At
least five airways were quantified per sample. All stained slides were scanned using a digital slide
scanner (Scanscope XT, Aperio Technologies, CA, USA) at 200X magnification. Photomicrographs of
stained sections were taken at 20, 40 and 100x magnification using an Olympus BX51 microscope.
Table 1. Primary antibodies.
Primary antibody (dilution) Clone Supplier
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Immunofluorescence
Lung sections were permeabilised with 0.5% Triton, blocked with 10% normal goat serum (Sigma-
Aldrich) and incubated overnight at 4˚C with anti-actin a-smooth muscle (1:400; Sigma-Aldrich) and
biotinylated mouse anti-PCNA (1:200; Zymed Laboratories, CA, U.S.A.). Sections were then stained
with goat anti-mouse AF488 (1:500; Invitrogen) and streptavidin AF647 (1:500; Invitrogen). Slides
were subsequently counterstained in 4’, 6-amino-2-phenylindole DAPI (final concentration: 0.5 mg/
ml) for five mins. Photomicrographs of airways were taken at 40X magnification using a fluorescent
microscope and the percentage of ASM cells positive for PCNA around the airway epithelial cells
were quantified from four airways per mouse.
Enzyme linked immunosorbent assay (ELISA)
Whole lung tissue was stored in radio immunoprecipitation (RIPA) buffer and homogenised using tis-
sue tearer homogeniser (BioSpec Products Inc, OK, U.S.A). Alternatively, BAL fluid was collected
and stored at  20˚C until analysis. Cytokine levels were measured according to the manufacturer’s
protocol (Biolegend, CA, U.S.A; Chondex, WA, U.S.A; R and D systems, MN, U.S.A.; PBL Assay Sci-
ence,Piscataway, NJ, U.S.A.). Detection limits were as follows: HMGB1 (1.6 ng/mL), IL-5 (4 pg/mL),
IL-17A (2 pg/mL), Eotaxin-2 (15.6), CXCL1 (7.8 pg/mL), IL-12p40 (7.8 pg/mL), IL-1b (7.8 pg/mL), IL-6
(2 pg/mL), IL-23 (8 pg/mL), CCL3 (7.8 pg/mL), TNFa (3.9 pg/mL), IFN-l (4 og/mL), IFN-a (5 pg/mL)
and IFN-g (4 pg/mL).
Cytokine bead analysis
Levels of IL-13 in BAL fluid were measured using a mouse IL-13 Flex Set (BD Biosciences; Detection
limit: 15.3 pg/mL).
Quantitative polymerase chain reaction (qPCR)
RNA was isolated from lung tissues by homogenisation with a sterile plastic pestle in 200 ml of TRI-
reagent (Ambion, TX, U.S.A.) according to the manufacturer’s protocol. DNase digestion was per-
formed using TURBO DNA-freeTM kit (Ambion). cDNA was generated from 1 mg of RNA using
Superscript Reverse Transcriptase (Invitrogen). Real time PCR was performed on generated cDNA
with SYBER Green (Invitrogen) using an ABI7900 system (Applied Biosystems, Victoria, Australia).
Forward and reverse primer sequences for each gene of interest are shown in Table 2. Gene expres-
sion was normalised relative to hypoxanthine phosphoribosyl transferase (HPRT) expression and fold
change was calculated using the DDCt method. PVM titres were analysed via qPCR as described pre-
viously (Davidson et al., 2011).
















PVM (SH domain) FW: gcctgcatcaacacagtgtgt
RV: gcctgatgtggcagtgctt
DOI: 10.7554/eLife.21199.017
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Airway resistance
Airway resistance was measured by the forced oscillation technique (FOT) using a flexiVent FX
machine (SCIEREQ, Quebec, Canada). Briefly, mice were anaesthetised and then mechanically venti-
lated. Increasing doses of nebulised methacholine (Sigma-Aldrich) were administered via the trachea
at concentrations of 0, 0.3, 1, 3, 10 mg/ml. The response to methacholine was expressed as a per-
centage change over the baseline control (saline).
Statistics
Graph Pad Prism software (version 6.00) was used for all statistical calculations. Data sets were ana-
lysed using unpaired Student’s t-test, 1 way or 2-way ANOVA with Tukey’s multiple comparison test.
Outliers within data sets were excluded based on a Grubb’s test/extreme studentised deviate (ESD)
test for variation from a normal distribution.
Study approval
All animal experiments were approved by The University of Queensland Animal Ethics and Experi-
mentation Committee.
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